(AOF) – Abionyx Pharma records consolidated turnover of 4.64 million euros for the 2023 financial year compared to 5.25 million euros in 2022. Its cash position amounts to 4.1 million euros as of December 31, 2023 compared to 4.04 million euros in 2022. Concerning the biotech activity dedicated to the discovery and development of innovative therapies aimed at improving the lives of patients, the company did not generate any turnover on this exercise.
The company recalls that beyond available cash of 4.1 million euros, Abionyx Pharma, with the arrival last January of Dr Rob Scott as CMO and head of R&D, favors the search for a partnership strategic.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
